Annovis Bio Shares Are Trading Lower After the Company Announced Data From Its Phase II/III Alzheimer Study of Buntanetap in Mild to Moderate Alzheimer's. Efficacy in the CGIC Endpoint Was Not Reached Due to the Limited Number of Patients and Short Trial Duration
Annovis Bio公布了其针对Buntanetap治疗轻度至中度阿尔茨海默氏症的II/III期阿尔茨海默氏症研究的数据后，该公司股价走低。由于患者数量有限且试验时间短，未达到CGIC终点的疗效